Paloma Partners’s Emergent Biosolutions EBS Stock Holding History

Paloma Partners’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-63,790	Closed	-$435K	–	1302
2024 Q2	$435K	Buy	+63,790	New	+$275K	0.01%	804
2020 Q3	–	Sell	-7,692	Closed	-$608K	–	2167
2020 Q2	$608K	Buy	+7,692	New	+$573K	0.01%	1144
2020 Q1	–	Sell	-4,480	Closed	-$242K	–	1450
2019 Q4	$242K	Sell	4,480 -4,997	-53%	-$271K	﹤0.01%	1880
2019 Q3	$495K	Buy	9,477 +4,827	+104%	+$225K	0.01%	1167
2019 Q2	$225K	Buy	4,650 +34	+0.7%	+$1.63K	﹤0.01%	1476
2019 Q1	$233K	Buy	+4,616	New	+$272K	0.01%	1437
2017 Q2	–	Sell	-12,586	Closed	-$366K	–	2229
2017 Q1	$366K	Sell	12,586 -14,683	-54%	-$447K	﹤0.01%	1681
2016 Q4	$895K	Buy	27,269 +14,733	+118%	+$442K	0.01%	1233
2016 Q3	$395K	Sell	12,536 -25,439	-67%	-$739K	﹤0.01%	1508
2016 Q2	$1.07M	Buy	37,975 +18,736	+97%	+$735K	0.01%	1108
2016 Q1	$699K	Buy	+19,239	New	+$680K	0.01%	1115

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Paloma Partners's EBS Position: Q3 2024 in Review

Paloma Partners sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 63,790 shares — an estimated $435K sold.

Paloma Partners first reported a position in EBS in Q1 2016 and held it in 11 quarters. The position peaked at $1.07M in Q2 2016. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

Paloma Partners reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 63,790 Emergent Biosolutions shares in Q3 2024, an estimated $435K.
Paloma Partners first reported a position in Emergent Biosolutions in Q1 2016 and held it in 11 quarters.
Paloma Partners's Emergent Biosolutions position peaked at $1.07M in Q2 2016.
140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.